

Applicants: Graham P. Allaway et al.
Serial No.: 09/904,356
Filed: July 12, 2001
Page 10

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following items, which are listed on the Substitute Form PTO-1449 attached hereto as **Exhibit C**. Items 1-6 are either U.S. Patents or U.S. Patent Application Publications. As permitted by 37 C.F.R. 1.98(a)(2)(ii), no copies of items 1-6 are included herewith. Copies of items 7-46 are attached hereto as **Exhibits 1-40**, respectively.

1. U.S. Patent No. 7,345,153 issued March 18, 2008 to Litwin, Virginia M. et al.
2. U.S. Patent Application Publication No. 2005-0131042 A1 published June 16, 2005 to Flentge, C.A.
3. U.S. Patent Application Publication No. 2002-0177603 A1 published November 28, 2002 to Johnson, B.L. et al.
4. U.S. Patent Application Publication No. 2006-0154857 A1, published July 13, 2006 to Redfield et al.;
5. U.S. Patent Application Publication No. 2007-0274986 A1, published November 29, 2007 to W.C. Olson and Paul J. Maddon;
6. U.S. Patent Application Publication No. 2007-0231327 A1, published October 4, 2007 to W.C. Olson and Paul J. Maddon;
7. Max, E. "Immunoglobulins: Molecular Genetics" in Fundamental Immunology, 6th edition. W.E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, 2008 pp. 192-236 (**Exhibit 1**);
8. Nelson et al. "Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced Patients Infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-Week results," 14th Annual Conference on Retroviruses and Opportunistic Infections. 28 Feb 2007. Abstract #104aLB (**Exhibit 2**);
9. Schroeder et al. (2008) "Immunoglobulins: Structure and Function," Fundamental Immunology, 6th Edition, Chapter 4, pp. 125-151 (**Exhibit 3**);
10. Combadiere, C. et al. (1995) Additions and Corrections to "Cloning and functional expression of a human eosinophil CC

Applicants: Graham P. Allaway et al.
Serial No.: 09/904,356
Filed: July 12, 2001
Page 11

chemokine receptor," J. Biol. Chem. 270(28) 16491-16494 (Exhibit 4);

11. June 18, 2008 Communication including Partial European Search Report in connection with European Patent Application No. 07 01 4859.8 (Exhibit 5);
12. September 19, 2008 Final Office Action issued in connection with U.S. Serial No. 09/460,216 (Exhibit 6);
13. July 9, 2008 Office Action issued in connection with U.S. Serial No. 11/258,963 (Exhibit 7);
14. July 1, 2008 Office Action issued in connection with U.S. Serial No. 11/581,944 (Exhibit 8);
15. January 9, 2008 Final Office Action issued in connection with U.S. Serial No. 11/258,963 (Exhibit 9);
16. May 29, 2008 Office Action issued in connection with U.S. Serial No. 11/259,540 (Exhibit 10);
17. April 9, 2008 Office Action issued in connection with U.S. Serial No. 11/451,707 (Exhibit 11);
18. November 2, 2007 Office Action issued in connection with U.S. Serial No. 11/805,573 (Exhibit 12);
19. September 21, 2007 Notice of Allowability issued in connection with U.S. Serial No. 11/544,346, now U.S. Patent No. 7,345,153 (Exhibit 13);
20. March 11, 2008 Office Action issued in connection with U.S. Serial No. 09/888,938 (Exhibit 14);
21. May 31, 2007 Office Action issued in connection with U.S. Serial No. 09/888,938 (Exhibit 15);
22. October 4, 2007 Office Action issued in connection with U.S. Serial No. 11/175,815 (Exhibit 16);
23. November 16, 2007 Office Action issued in connection with U.S. Serial No. 09/460,216 (Exhibit 17);
24. September 12, 2007 Final Office Action issued in connection with U.S. Serial No. 11/400,497 (Exhibit 18);
25. April 3, 2008 Office Action issued in connection with U.S. Serial No. 11/520,556 (Exhibit 19);

Applicants: Graham P. Allaway et al.
Serial No.: 09/904,356
Filed: July 12, 2001
Page 12

26. January 9, 2008 Office Action issued in connection with U.S. Serial No. 11/259,540 (**Exhibit 20**);
27. May 22, 2008 Office Action issued in connection with U.S. Serial No. 11/491,330 (**Exhibit 21**);
28. August 5, 2008 Final Office Action issued in connection with U.S. Serial No. 11/175,815 (**Exhibit 22**);
29. August 19, 2008 Office Action issued in connection with U.S. Serial No. 11/804,746 (**Exhibit 23**);
30. September 11, 2008 Office Action issued in connection with U.S. Serial No. 11/805,573 (**Exhibit 24**);
31. April 9, 2008 Office Action issued in connection with U.S. Serial No. 11/316,078 (**Exhibit 25**);
32. May 14, 2008 Office Action issued in connection with U.S. Serial No. 11/400,497 (**Exhibit 26**);
33. Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, Or the Declaration issued July 25, 2008 in connection with PCT International Application No. PCT/US06/28565 (**Exhibit 27**);
34. Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, Or the Declaration issued August 15, 2008 in connection with PCT International Application No. PCT/US08/05564 (**Exhibit 28**);
35. May 15, 2008 Office Action issued in connection with U.S. Serial No. 11/581,945 (**Exhibit 29**);
36. September 16, 2008 Communication including a May 29, 2008 Extended European Search report in connection with European Patent Application No. 07014859.8 (**Exhibit 30**);
37. PCT International Application Publication No. WO 94/19017, published September 1, 1994 (**Exhibit 31**);
38. October 2, 2008 Communication Pursuant to Article 94(3) EPC and Result of Consultation issued in connection with European Patent Application No. 01970984.9 (**Exhibit 32**);

Applicants: Graham P. Allaway et al.
Serial No.: 09/904,356
Filed: July 12, 2001
Page 13

39. Office Action issued November 10, 2008 in connection with U.S. Serial No. 11/400,497 (**Exhibit 33**);
40. Office Action issued December 12, 2008 in connection with U.S. Serial No. 11/491,330 (**Exhibit 34**);
41. Final Office Action issued December 31, 2008 in connection with U.S. Serial No. 11/581,945 (**Exhibit 35**);
42. Final Office Action issued January 9, 2009 in connection with U.S. Serial No. 11/451,707 (**Exhibit 36**);
43. Final Office Action issued January 27, 2009 in connection with U.S. Serial No. 11/259,540 (**Exhibit 37**);
44. Final Office Action issued January 27, 2009 in connection with U.S. Serial No. 11/520,556 (**Exhibit 38**);
45. Simmons, G. et al. (1996) "Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry," J. Virol. 70(12):8355-8360 (**Exhibit 39**);
46. Valentin, A. et al. (1994) "Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates," J. Virol. 68(10):6684-6689 (**Exhibit 40**).

This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. 1.97(c)(2). Accordingly, applicants enclose herewith a check including the amount of \$180.00.

The Examiner is respectfully requested to make the listed items of record in the present application by initialing and returning a copy of the enclosed Substitute Form PTO 1449.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Graham P. Allaway et al.
Serial No.: 09/904,356
Filed: July 12, 2001
Page 14

No fee, other than the total enclosed fee of \$735.00, including a \$555.00 fee for a three-month extension of time, and a \$180.00 fee for filing an Information Disclosure Statement, is deemed necessary in connection with the filing of this Amendment and Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham, LLP
Customer No. 079057
30 Rockefeller Plaza, 20th Flr.
New York, New York 10112
(212) 278-0400

I hereby certify that this correspondence is being deposited on this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450.

 2/19/09

John P. White	Date
Reg. No. 28,678	